209 related articles for article (PubMed ID: 34337986)
21. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
22. Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.
Tomaszewski D
J Manag Care Spec Pharm; 2016 Aug; 22(8):919-26. PubMed ID: 27459654
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy.
Giavatto C; Mourani J; Fitzpatrick C; Hardin B; Skrtic A; Evans A; Sredzinski E; Trieu S; Setter AI; Kobiska L; Lopez-Medina AI
J Manag Care Spec Pharm; 2024 Feb; 30(2):175-182. PubMed ID: 38308629
[TBL] [Abstract][Full Text] [Related]
24. AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection.
J Manag Care Spec Pharm; 2020 Jan; 26(1):55-62. PubMed ID: 31880226
[TBL] [Abstract][Full Text] [Related]
25. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
26. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
27. Pharmacist biosimilar survey reveals knowledge gaps.
Stevenson JG; McCabe D; McGrath M; McBride A
J Am Pharm Assoc (2003); 2023; 63(2):529-537.e7. PubMed ID: 36437154
[TBL] [Abstract][Full Text] [Related]
28. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
29. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
30. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
31. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
32. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
33. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
Shubow S; Sun Q; Nguyen Phan AL; Hammell DC; Kane M; Lyman GH; Gibofsky A; Lichtenstein GR; Bloomgarden Z; Cross RK; Yim S; Polli JE; Wang YM
Clin Pharmacol Ther; 2023 Jan; 113(1):37-49. PubMed ID: 36251545
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
35. Biosimilar strategic implementation at a large health system.
Kar I; Kronz M; Kolychev E; Silverman P; Mendiratta P; Tomlinson BKN; Prunty J; Copley M; Patel S; Caudill S; Farah L; Wesolowski B; Crissinger T; Kendig C; Szymczak E; Duraj L; Dumot J; Acheson E; Lyamkin S; King M; Mocilnikar A; Cunningham K; Paulic N; Botzki U; Lerman R; Strosaker R; Osborne S; Glotzbecker B
Am J Health Syst Pharm; 2022 Feb; 79(4):268-275. PubMed ID: 34752608
[TBL] [Abstract][Full Text] [Related]
36. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
37. Pharmacists' Perspectives of Biosimilars: A Systematic Review.
Mohd Sani N; Aziz Z; Panickar R; Kamarulzaman A
BioDrugs; 2022 Jul; 36(4):489-508. PubMed ID: 35776294
[TBL] [Abstract][Full Text] [Related]
38. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
[TBL] [Abstract][Full Text] [Related]
39. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
Hair J; Maryon T; Lieneck C
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
[TBL] [Abstract][Full Text] [Related]
40. Provider and patient knowledge gaps on biosimilars: insights from surveys.
Gibofsky A; Evans C; Strand V
Am J Manag Care; 2022 Nov; 28(12 Suppl):S227-S233. PubMed ID: 36493396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]